Reuters logo
BRIEF-Galapagos announces new phase 2 study with filgotinib
2017年7月5日 / 凌晨5点46分 / 5 个月前

BRIEF-Galapagos announces new phase 2 study with filgotinib

July 5 (Reuters) - GALAPAGOS NV

* NEW PHASE 2 STUDY WITH FILGOTINIB IN NON-INFECTIOUS UVEITIS‍​

* STUDY LED BY FILGOTINIB COLLABORATION PARTNER GILEAD SCIENCES, INC.‍​

* PRIMARY OUTCOME IS MEASURED BY THE PROPORTION OF SUBJECTS FAILING TREATMENT BY WEEK 24; TREATMENT FAILURE IS REPRESENTATIVE OF AN ACTIVE UVEITIS FLARE.

* APPROXIMATELY 110 PATIENTS ARE PLANNED TO BE RANDOMIZED IN THE STUDY TO RECEIVE FILGOTINIB OR PLACEBO ADMINISTERED FOR 52 WEEKS‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below